Mizuho Reiterates “Buy” Rating for Viveve Medical (VIVE)

Viveve Medical (NASDAQ:VIVE)‘s stock had its “buy” rating reiterated by equities research analysts at Mizuho in a research note issued to investors on Thursday.

The analysts wrote, “We spoke with the CFO, Scott Durbin post announcement this morning. Scott emphasized that while the discounted price of $3.00 relative to yesterday’s closing ($3.83) was disappointing, the newly raised capital is adequate to support continued business expansion into the end of 2019 and removes a financing overhang. The company is still hopeful in receiving clearance from the FDA to run the sexual dysfunction study by the end of Q1, 2018.””

A number of other research firms also recently issued reports on VIVE. Ladenburg Thalmann Financial Services restated a “buy” rating on shares of Viveve Medical in a research report on Thursday, January 4th. ValuEngine downgraded shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Northland Securities started coverage on shares of Viveve Medical in a research report on Friday, January 5th. They issued an “outperform” rating and a $8.00 price target on the stock. Finally, Cowen set a $11.00 price target on shares of Viveve Medical and gave the stock a “buy” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $10.00.

Viveve Medical (VIVE) traded down $0.16 during midday trading on Thursday, reaching $3.67. 1,528,127 shares of the company’s stock were exchanged, compared to its average volume of 204,320. Viveve Medical has a 12-month low of $3.45 and a 12-month high of $11.16. The company has a quick ratio of 3.63, a current ratio of 3.89 and a debt-to-equity ratio of 2.72. The company has a market cap of $77.51, a P/E ratio of -1.70 and a beta of -0.79.

Viveve Medical (NASDAQ:VIVE) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.08). Viveve Medical had a negative return on equity of 275.77% and a negative net margin of 257.58%. The business had revenue of $4.07 million during the quarter, compared to the consensus estimate of $4.10 million. During the same quarter in the previous year, the business posted ($0.46) earnings per share. The company’s quarterly revenue was up 120.1% compared to the same quarter last year. research analysts predict that Viveve Medical will post -2.05 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Rhumbline Advisers bought a new position in shares of Viveve Medical in the 2nd quarter worth about $110,000. JPMorgan Chase & Co. acquired a new stake in shares of Viveve Medical in the 2nd quarter worth about $151,000. Virtu KCG Holdings LLC acquired a new stake in shares of Viveve Medical in the 2nd quarter worth about $169,000. ING Groep NV increased its holdings in shares of Viveve Medical by 7.7% in the 4th quarter. ING Groep NV now owns 350,000 shares of the company’s stock worth $1,740,000 after acquiring an additional 25,000 shares during the period. Finally, Granahan Investment Management Inc. MA increased its holdings in shares of Viveve Medical by 32.6% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 102,147 shares of the company’s stock worth $535,000 after acquiring an additional 25,097 shares during the period. Institutional investors own 66.89% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Mizuho Reiterates “Buy” Rating for Viveve Medical (VIVE)” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/08/mizuho-reiterates-buy-rating-for-viveve-medical-vive.html.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply